The economic evaluation of a vaccination against pertussis infection in children in Moscow

Actuality. Previously, we calculated the economic consequences of the booster vaccination against pertussis infection (CI) with the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, combined, adsorbed (INN) in some regions of the Russian Federation, which showed that the public benefit within 7 years after immunization could potentially exceed the cost of vaccination 1.23 times. At the same time, it is important to provide an economic justification for vaccination for a megalopolis, such as Moscow, with an underestimation of the diagnosis of the disease in conditions of high population density, contributing to the spread of infection. Materials and methods. The assessment of the economic benefits of obtaining an epidemiological gain during revaccination was carried out within the framework of a market economy using an assessment of the cost of the disease. The calculations were based on data on the cost of CI treatment in Moscow, considering cases of complicated and mild course and on the basis of current tariffs of the OMI system. Modeling was performed based on morbidity rates, taking into account the underestimation of detectability in a cohort of 14-year-olds numbering 100 thousand people. Two scenarios were compared, providing for the preservation of the existing procedure of revaccination only at 6 years (95% coverage) and the scenario in which the second revaccination of all adolescents was carried out at 14 years. Using the model, epidemiological indicators of changes in the incidence of CI were determined, and direct and indirect costs were calculated on their basis. When testing the sensitivity of the model, other levels of vaccination of 14-year-old children were also used in the calculations. Results. Booster revaccination of a conditional cohort of 100,000 children aged 14 years with the mentioned vaccine will reduce the incidence of pertussis during the period of saving immune protection (7 years) by 53.7% (from 1702.5 to 788.4 cases per 100 thousand of the population of these ages). This epidemiological gain will be accompanied by an economic benefit calculated in the metric of the total cost of prevented cases of the disease, which will amount to 155.4 million rubles. For a cohort of 100 thousand revaccinated adolescents of 14 years. The economic benefits accompanying a potential reduction in the incidence of infants can range from 254.4 to 470.5 million rubles, depending on the nature and intensity of contacts between adolescents and younger children. Conclusion. With the given parameters of underestimating the diagnosis and cost of the vaccine in the population over 14 years of age in Moscow, revaccination of adolescents is an economically justified measure.

1. Светличная С.В., Елагина Л.А., Попович Л.Д. Оценка экономической эффективности вакцинации против коклюша на основе данных реальной клинической практики. Реальная клиническая практика: данные и доказательства. 2023;3(1):9-19. https://doi.org/10.37489/2782-3784-myrwd-27 [SvetlichnayaSV,ElaginaLA, Popovich LD. Evaluation of the economic efficacy of vaccination against pertussis based on real-world data. Real-World Data & Evidence. 2023;3(1):9-19. (In Russ.)].

2. Федеральная служба государственной статистики https://rosstat.gov.ru/. Дата обращения: 14.03.2023.

3. Приказ департамента здравоохранения города Москвы от 18.11.2019 № 975 «Об утверждении регионального календаря профилактических прививок и регионального календаря профилактических прививок по эпидемическим показаниям». https://base.garant.ru/73322997/. Дата обращения: 10.03.2023.

4. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в городе Москве в 2021 году». Управление Роспотребнадзора по г. Москве. https://77.rospotrebnadzor.ru/. Дата обращения: 12.03.2023.

5. Статистическая Форма №2 Сведения об инфекционных и паразитарных заболеваниях. 2018, 2019 гг. https://rospotrebnadzor.ru/. Дата обращения: 16.08.2022.

6. Намазова Л.С., Геворкян А.К., Галеева Е.А. Является ли коклюш проблемой для российской педиатрии, и можем ли мы его победить? Педиатрическая фармакология. 2006; 3(4):6-9.

7. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005 May;115(5):1422-1427. DOI: 10.1542/ peds.2004-2648. PMID: 15867059.

8. Резолюция междисциплинарного совещания специалистов «Нерешенные вопросы эпидемиологии коклюша в РФ и новые возможности его вакцинопрофилактики». Эпидемиология и Вакцинопрофилактика. 2018;17(4):63-67. https://doi.org/10.31631/2073-3046-2018-17-4-63-67 [The interdisciplinary Meeting of Experts’s Resolution «Unresolved Questions of Pertussis Epidemiology in the Russian Federation and the New Possibilities for Vaccination». Epidemiology and Vaccinal Prevention. 2018;17(4):63-67. (In Russ.)].

9. Михеева И.В., Михеева М.А. Оценка экономической эффективности ревакцинации против коклюша детей дошкольного возраста. Вопросы современной педиатрии. 2019;18(6):470-477. https://doi.org/10.15690/vsp.v18i6.2068 [Mikheeva IV, Mikheeva MA. Cost-Effectiveness Analysis of Revaccination Against Pertussis in Preschool Children. Current Pediatrics. 2019;18(6):470-477. (In Russ.)].

10. Forsyth KD, Tan T, von König CW, Heininger U, Chitkara AJ, Plotkin S. Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update. Vaccine. 2018 Nov 19;36(48):7270-7275. doi: 10.1016/j.vaccine.2018.10.028. Epub 2018 Oct 15. PMID: 30337176.

11. Басов А.А. Эпидемический процесс коклюша на современном этапе. Автореф. дисс. канд. мед наук. М., 2016. 20 c. https://www.crie.ru/pdf/disser1(basov).pdf.

12. Таточенко В.К. Коклюш — недоуправляемая инфекция. Вопросы современной педиатрии. 2014; 13(2):78-82. https://doi.org/10.15690/vsp.v13i2.975 [Tatochenko VK. Pertussis — infection not under complete control. Current Pediatrics. 2014;13(2):78-82. (In Russ.)].

13. Брико Н.И., Миндлина А.Я., Михеева И.В., Попович Л.Д., Ломоносова А.В. Моделирование потенциального эффекта ревакцинации против коклюша детей в 6–7 и 14 лет в рамках национального календаря профилактических прививок. Эпидемиология и Вакцинопрофилактика. 2021;20(5):4-20. https://doi.org/10.31631/2073-3046-2021-20-5-4-20 [Briko NI, Mindlina AY, Mikheeva IV, Popovich LD, Lomonosova AV. Modeling of the Potential Effect of Revaccination against Whooping Cough in Children Aged 6–7 and 14 years within the Framework of the National of preventive vaccinations. Epidemiology and Vaccinal Prevention. 2021;20(5):4-20. (In Russ.)].

14. Carlsson RM, von Segebaden K, Bergstrom J, Kling AM, Nilsson L. Surveillance of infant pertussis in Sweden 1998-2012; severity of disease in relation to the national vaccination programme. Euro Surveill. 2015 Feb 12;20(6):21032. doi: 10.2807/1560-7917. es2015.20.6.21032. PMID: 25695476.

15. Михеева И.В., Фомкина Н.Н., Михеева М.А. Современная эпидемиологическая и экономическая характеристика коклюша в Москве. Журнал инфектологии. 2019;11(1):84-91. https://doi.org/10.22625/2072-6732-2019-11-1-84-91 [Mikheeva IV, Fomkina NN, Mikheeva MA. Modern epidemiological and economic characteristics of whooping cough in Moscow. Journal Infectology. 2019;11(1):84-91. (In Russ.)].

16. Фармакоэкономика и фармакоэпидемиология — практика приемлемых решений / Ред. В.Б. Герасимов, А.Л. Хохлов, О.И. Карпов. — М.: Медицина; 2005, 352 с.